+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID04499053

Phase II Study of Durvalumab and Tremelimumab with Platinum Chemotherapy for Stage IV Non-Small Cell Lung Cancer in Patients with HIV

Led by Georgetown University · Updated on 2026-03-16

18

Participants Needed

4

Research Sites

43 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the safety and effectiveness of durvalumab and tremelimumab combined with standard platinum-based chemotherapy in patients with stage IV Non-Small-Cell Lung Cancer NSCLC who also have HIV infection. This phase II trial focuses on this specific population to understand how these treatments work together in this context. Participants will receive four cycles of treatment every three weeks, including durvalumab 1500 mg, tremelimumab 75 mg, and platinum-based chemotherapy tailored to tumor type. After these induction cycles, patients showing stable disease or better may continue maintenance therapy with durvalumab every four weeks, with or without pemetrexed for non-squamous NSCLC. A single additional dose of tremelimumab is given at week 16. During the study, researchers will monitor adverse events and tumor response using established criteria after four cycles. They will also assess changes in HIV viral load and immune markers over time. Participants will undergo regular visits, scans, and laboratory tests to evaluate treatment effects and safety. The study plans to enroll up to 18 patients and will continue until December 2027.

CONDITIONS

Brief Title

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here